SUMO and Its Role in Human Diseases

International Review of Cell and Molecular Biology

Volumn 288, Issue , 2011, Pages 167-183

  Sarge, Kevin D ^a   Park Sarge, Ok Kyong ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

ALS; Alzheimer's disease; Amyotrophic lateral sclerosis; APP; Cancer; DJ 1; Heart; Lamin; Laminopathy; Parkinson's disease; SOD1; SUMO; SUMO 1; Sumoylation; Tau; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ATAXIN 1; COPPER ZINC SUPEROXIDE DISMUTASE; DJ 1 PROTEIN; HUNTINGTIN; LAMIN A; PROTEIN UBC9; SUMO PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BOOK; CARCINOGENESIS; CONGESTIVE CARDIOMYOPATHY; COVALENT BOND; HUMAN; HUNTINGTON CHOREA; LIVER CELL CARCINOMA; MUTATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SPINOCEREBELLAR DEGENERATION; SUMOYLATION; THYROID CANCER;

EID: 79953769235     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-386041-5.00004-2     Document Type: Chapter

References (76)

1. Anckar J., Sistonen L. SUMO: getting it on. Biochem. Soc. Trans. 2007, 35:1409-1413.
2. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
3. Bendtsen J.D., Jensen L.J., Blom N., Von Heijne G., Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 2004, 17:349-356.
4. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
5. Bohren K.M., Gabbay K.H., Owerbach D. Affinity chromatography of native SUMO proteins using His-tagged recombinant UBC9 bound to Co2+-charged talon resin. Protein Expr. Purif. 2007, 54:289-294.
6. Boillee S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
7. Broers J.L., Ramaekers F.C., Bonne G., Yaou R.B., Hutchison C.J. Nuclear lamins: laminopathies and their role in premature ageing. Physiol. Rev. 2006, 86:967-1008.
8. Capell B.C., Collins F.S. Human laminopathies: nuclei gone genetically awry. Nat. Rev. Genet. 2006, 7:940-952.
9. Cheng J., Bawa T., Lee P., Gong L., Yeh E.T. Role of desumoylation in the development of prostate cancer. Neoplasia 2006, 8:667-676.
10. Denison C., Rudner A.D., Gerber S.A., Bakalarski C.E., Moazed D., Gygi S.P. A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol. Cell. Proteomics 2005, 4:246-254.
11. Desterro J.M., Thomson J., Hay R.T. Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett. 1997, 417:297-300.
12. Desterro J.M., Rodriguez M.S., Kemp G.D., Hay R.T. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 1999, 274:10618-10624.
13. Dorval V., Fraser P.E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J. Biol. Chem. 2006, 281:9919-9924.
14. Dorval V., Mazzella M.J., Mathews P.M., Hay R.T., Fraser P.E. Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem. J. 2007, 404:309-316.
15. Fatkin D., MacRae C., Sasaki T., Wolff M.R., Porcu M., Frenneaux M., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N. Engl. J. Med. 1999, 341:1715-1724.
16. Fei E., Jia N., Yan M., Ying Z., Sun Q., Wang H., et al. SUMO-1 modification increases human SOD1 stability and aggregation. Biochem. Biophys. Res. Commun. 2006, 347:406-412.
17. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
18. Gocke C.B., Yu H., Kang J. Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates. J. Biol. Chem. 2005, 280:5004-5012.
19. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
20. Gong L., Li B., Millas S., Yeh E.T. Molecular cloning and characterization of human AOS1 and UBA2, components of the sentrin-activating enzyme complex. FEBS Lett. 1999, 448:185-189.
21. Gonzalez de Aguilar J.L., Echaniz-Laguna A., Fergani A., Rene F., Meininger V., Loeffler J.P., et al. Amyotrophic lateral sclerosis: all roads lead to Rome. J. Neurochem. 2007, 101:1153-1160.
22. Hang J., Dasso M. Association of the human SUMO-1 protease SENP2 with the nuclear pore. J. Biol. Chem. 2002, 277:19961-19966.
23. Hannich J.T., Lewis A., Kroetz M.B., Li S.J., Heide H., Emili A., et al. Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J. Biol. Chem. 2005, 280:4102-4110.
24. Jacques C., Baris O., Prunier-Mirebeau D., Savagner F., Rodien P., Rohmer V., et al. Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. J. Clin. Endocrinol. Metab. 2005, 90:2314-2320.
25. Jakobs P.M., Hanson E.L., Crispell K.A., Toy W., Keegan H., Schilling K., et al. Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease. J. Card. Fail. 2001, 7:249-256.
26. Johnson E.S., Blobel G. Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J. Biol. Chem. 1997, 272:26799-26802.
27. Johnson E.S., Gupta A.A. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 2001, 106:735-744.
28. Johnson E.S., Schwienhorst I., Dohmen R.J., Blobel G. The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J. 1997, 16:5509-5519.
29. Kagey M.H., Melhuish T.A., Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 2003, 113:127-137.
30. Kahyo T., Nishida T., Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell 2001, 8:713-718.
31. Kim K.I., Baek S.H. SUMOylation code in cancer development and metastasis. Mol. Cells 2006, 22:247-253.
32. Koldamova R.P., Lefterov I.M., DiSabella M.T., Lazo J.S. An evolutionarily conserved cysteine protease, human bleomycin hydrolase, binds to the human homologue of ubiquitin-conjugating enzyme 9. Mol. Pharmacol. 1998, 54:954-961.
33. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
34. Lee J.S., Thorgeirsson S.S. Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology 2004, 127:S51-S55.
35. Lee G.W., Melchior F., Matunis M.J., Mahajan R., Tian Q., Anderson P. Modification of Ran GTPase-activating protein by the small ubiquitin-related modifier SUMO-1 requires Ubc9, an E2-type ubiquitin-conjugating enzyme homologue. J. Biol. Chem. 1998, 273:6503-6507.
36. Li Y., Wang H., Wang S., Quon D., Liu Y.W., Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc. Natl. Acad. Sci. USA 2003, 100:259-264.
37. Lindwall G., Cole R.D. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 1984, 259:5301-5305.
38. Mattout A., Dechat T., Adam S.A., Goldman R.D., Gruenbaum Y. Nuclear lamins, diseases and aging. Curr. Opin. Cell Biol. 2006, 18:335-341.
39. McDoniels-Silvers A.L., Nimri C.F., Stoner G.D., Lubet R.A., You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin. Cancer Res. 2002, 8:1127-1138.
40. Meulmeester E., Kunze M., Hsiao H.H., Urlaub H., Melchior F. Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25. Mol. Cell 2008, 30:610-619.
41. Mo Y.Y., Yu Y., Theodosiou E., Ee P.L., Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 2005, 24:2677-2683.
42. Mukhopadhyay D., Dasso M. Modification in reverse: the SUMO proteases. Trends Biochem. Sci. 2007, 32:286-295.
43. Mullan M., Crawford F., Axelman K., Houlden H., Lilius L., Winblad B., et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat. Genet. 1992, 1:345-347.
44. Okuma T., Honda R., Ichikawa G., Tsumagari N., Yasuda H. In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun. 1999, 254:693-698.
45. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 2007, 30:575-621.
46. Parnaik V.K., Manju K. Laminopathies: multiple disorders arising from defects in nuclear architecture. J. Biosci. 2006, 31:405-421.
47. Pichler A., Gast A., Seeler J.S., Dejean A., Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108:109-120.
48. Riley B.E., Zoghbi H.Y., Orr H.T. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J. Biol. Chem. 2005, 280:21942-21948.
49. Rodriguez M.S., Dargemont C., Hay R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 2001, 276:12654-12659.
50. Rothstein J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009, 65:S3-S9.
51. Ryu J., Cho S., Park B.C., Lee do H. Oxidative stress-enhanced SUMOylation and aggregation of ataxin-1: Implication of JNK pathway. Biochem. Biophys. Res. Commun. 2010, 393:280-285.
52. Sampson D.A., Wang M., Matunis M.J. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification. J. Biol. Chem. 2001, 276:21664-21669.
53. Seeler J.S., Bischof O., Nacerddine K., Dejean A. SUMO, the three Rs and cancer. Curr. Top. Microbiol. Immunol. 2007, 313:49-71.
54. Shinbo Y., Niki T., Taira T., Ooe H., Takahashi-Niki K., Maita C., et al. Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ. 2006, 13:96-108.
55. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
56. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
57. Takahashi K., Taira T., Niki T., Seino C., Iguchi-Ariga S.M., Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J. Biol. Chem. 2001, 276:37556-37563.
58. Takahashi Y., Kahyo T., Toh E.A., Yasuda H., Kikuchi Y. Yeast Ull1/Siz1 is a novel SUMO1/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates. J. Biol. Chem. 2001, 276:48973-48977.
59. Takahashi K., Ishida M., Komano H., Takahashi H. SUMO-1 immunoreactivity co-localizes with phospho-Tau in APP transgenic mice but not in mutant Tau transgenic mice. Neurosci. Lett. 2008, 441:90-93.
60. Thomas B., Beal M.F. Parkinson's disease. Hum. Mol. Genet. 2007, 16(Spec No. 2):R183-R194.
61. Ulrich H.D. The fast-growing business of SUMO chains. Mol. Cell 2008, 32:301-305.
62. Verstraeten V.L., Broers J.L., Ramaekers F.C., van Steensel M.A. The nuclear envelope, a key structure in cellular integrity and gene expression. Curr. Med. Chem. 2007, 14:1231-1248.
63. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
64. Wang L., Banerjee S. Differential PIAS3 expression in human malignancy. Oncol. Rep. 2004, 11:1319-1324.
65. Wang Z.Q., Zhou H.Y., Chen S.D. The role of DJ-1 in the pathogenesis of Parkinson's disease. Neurosci. Bull. 2006, 22:232-234.
66. Wykoff D.D., O'Shea E.K. Identification of sumoylated proteins by systematic immunoprecipitation of the budding yeast proteome. Mol. Cell. Proteomics 2005, 4:73-83.
67. Yeh E.T. SUMOylation and de-SUMOylation: Wrestling with life's processes. J. Biol. Chem. 2009, 284:8223-8227.
68. Zhang Y.Q., Sarge K.D. Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels. Biochem. Biophys. Res. Commun. 2008, 374:673-678.
69. Zhang Y.Q., Sarge K.D. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies. J. Cell Biol. 2008, 182:35-39.
70. Zhang H., Saitoh H., Matunis M.J. Enzymes of the SUMO modification pathway localize to filaments of the nuclear pore complex. Mol. Cell. Biol. 2002, 22:6498-6508.
71. Zhao J. Sumoylation regulates diverse biological processes. Cell. Mol. Life Sci. 2007, 64:3017-3033.
72. Zhong N., Xu J. Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1alpha: regulation by SUMOylation and oxidation. Hum. Mol. Genet. 2008, 17:3357-3367.
73. Zhong N., Radu G., Ju W., Brown W.T. Novel progerin-interactive partner proteins hnRNP E1, EGF, Mel 18, and UBC9 interact with lamin A/C. Biochem. Biophys. Res. Commun. 2005, 338:855-861.
74. Zhong N., Kim C.Y., Rizzu P., Geula C., Porter D.R., Pothos E.N., et al. DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor. J. Biol. Chem. 2006, 281:20940-20948.
75. Zhou W., Ryan J.J., Zhou H. Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J. Biol. Chem. 2004, 279:32262-32268.
76. Zoghbi H.Y., Orr H.T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 2009, 284:7425-7429.